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Single monosomy as a relatively better survival factor in acute
myeloid leukemia patients with monosomal karyotype
JE Jang1, YH Min1, J Yoon2, I Kim3, J-H Lee4, CW Jung5, H-J Shin6, WS Lee7, JH Lee8, D-S Hong9, H-J Kim10, H-J Kim2, S Park3, K-H Lee4,
JH Jang5, JS Chung6, SM Lee7, J Park8, SK Park9, J-S Ahn10, W-S Min2 and J-W Cheong1on behalf of the Korean Society of Hematology
AML/MDS Working Party
Monosomal karyotype (MK) deﬁned by either ⩾ 2 autosomal monosomies or single monosomy with at least one additional
structural chromosomal abnormality is associated with a dismal prognosis in patients with acute myeloid leukemia (AML). It was
detected in 174 of 3041 AML patients in South Korean Registry. A total of 119 patients who had received induction therapy were
ﬁnally analyzed to evaluate the predictive factors for a positive prognosis. On multivariate analysis, single monosomy, the absence
of abn(17p), ⩾ 10% of cells with normal metaphase and the achievement of a complete remission (CR) after induction therapy were
signiﬁcant factors for more favorable outcomes. Especially, single monosomy remained as a signiﬁcantly independent prognostic
factor for superior survival in both patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) in CR and
who did not. Allo-HSCT in CR improved overall survival signiﬁcantly only in patients with a single monosomy. Our results suggest
that MK-AML may be biologically different according to the karyotypic subtype and that allo-HSCT in CR should be strongly
recommended to patients with a single monosomy. For other patients, more prudent treatment strategies should be examined.
Furthermore, the biological mechanism by which a single monosomy inﬂuences survival should be investigated.
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INTRODUCTION
Although several different cytogenetic classiﬁcations exist for
acute myeloid leukemia (AML), it has been generally agreed that
speciﬁc cytogenetic abnormalities result in unfavorable prog-
noses. Adverse cytogenetic risk factors include − 5/5q deletion (del
(5q)), − 7/7q deletion (del(7q)), − 17/17p abnormality (abn(17p)),
inv(3)(q21q26/t(3;3)(q21;q26) and complex karyotype (CK).1–4
Recently, monosomal karyotype (MK) has been shown to be
associated with a dismal prognosis in AML, and it has gotten
another prognostic value in AML patients compared with CK.5–9
This new category is deﬁned by either the presence of two
autosomal monosomies or one monosomy with at least one
additional structural chromosomal abnormality (in the absence of
core-binding factor AML and acute promyelocytic leukemia).5
Although a higher percent of cells with normal metaphases or
absence of abn(17p) or − 5/del(5q) in MK-AML may be associated
with prognosis,10,11 studies for clinical signiﬁcance according to
the karyotypic heterogeneity or subtype of MK is limited. The
beneﬁts of allogeneic hematopoietic stem cell transplantation
(allo-HSCT) in patients with MK have also been controversial.
Several retrospective analyses have suggested that allo-HSCT
would be associated with improved survival.12,13 In contrast,
Kayser et al.7 reported no signiﬁcant beneﬁt from allo-HSCT in
patients achieving complete remission (CR) after induction
therapy.
Therefore, to clarify the predictors of improved outcome and to
determine appropriate indication for allo-HSCT for MK-AML
patients, this study investigated the inﬂuence of speciﬁc clinical
and karyotypic characteristics on prognosis, as well as proper
therapeutic strategies for MK-AML patients.
PATIENTS AND METHODS
Patients
For this study, nationwide database of Korean AML Registry, which has
been operated from 2007 by the Korean Society of Hematology AML/
Myelodysplastic Syndrome Working Party, was analyzed. A total of 3041
AML patients from 28 institutions were registered at the time of analysis.
The cohort included 1679 male and 1356 female, with a median age of 51
years (range, 16–87 years). AML was diagnosed according to the World
Health Organization deﬁnition of420% blasts in the bone marrow (BM) or
peripheral blood.14 Patients without cytogenetic analysis, those in whom
cytogenetic analysis failed and those with core-binding factor abnormal-
ities or acute promyelocytic leukemia were excluded from this study.
From January 2007 to December 2011, 174 patients (5.7%) who met the
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deﬁnition of MK-AML were selected for this study, and ﬁnally 119 patients
from 10 institutions who received induction therapy were retrospectively
analyzed. The study protocol was approved by each institution’s
institutional review board.
Cytogenetic and molecular analysis
Cytogenetic analysis was performed using metaphasic cells from BM
aspirates obtained at diagnosis using the conventional G-banding method.
Karyotype designation was based on the International System for Human
Cytogenetic Nomenclature.15 Only clonal abnormalities were considered
positive results. Abnormalities were considered clonal if ⩾ 2 metaphases
had the same aberration in the case of a structural abnormality or an extra
chromosome, or if ⩾ 3 metaphases shared the same abnormality in the
case of a monosomy. CK was deﬁned as ⩾ 3 clonal abnormalities or ⩾ 4
clonal abnormalities. The MK was deﬁned as the presence of two
autosomal monosomies or one monosomy with at least one additional
structural chromosomal abnormality, as previously reported by Breems
et al.5
Statistical analysis
The distribution of patients’ characteristics between groups was compared
using the χ2 or Fisher's exact tests for categorical variables and the Mann–
Whitney U-test for continuous variables. Overall survival (OS) was deﬁned
as the time from the date of AML diagnosis to the date of death or the last
follow-up. Event-free survival (EFS) was deﬁned for all patients and was
measured from the date of AML diagnosis until treatment failure, relapse
from CR or death from any cause, whichever occurred ﬁrst. Relapse-free
survival (RFS) in patients achieving CR after induction chemotherapy was
calculated from the date of CR achievement until the date of relapse or
death from any cause. When comparing the survival of patients who
underwent allo-HSCT, OS and EFS were calculated from the date of allo-
HSCT. Logistic regression was used to test for the factors associated with
the achievement of CR in univariate and multivariate analyses. A Kaplan–
Meier survival analysis was performed to estimate the probabilities of
survival. Differences in survival between groups were compared using the
log-rank test. Factors affecting OS, EFS and RFS were analyzed using the
Cox proportional hazards model in univariate and multivariate analyses.
Po0.05 was deﬁned as statistically signiﬁcant. All statistical analyses were
performed using SPSS, version 20.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
The baseline characteristics of 119 MK-AML patients are summar-
ized in Table 1. The median age was 56 years (range, 17–82 years);
83 patients (69.7%) were male and 36 patients (30.3%) were
female. Nineteen patients (16%) were secondary AML developed
following exposure to cytotoxic agents or as a subsequent event
in another hematologic disorder, and most patients (89.1%) had
CK (⩾3 clonal abnormalities). The most frequent cytogenetic
abnormalities were − 7/7q deletion (47.1%), and − 5/5q deletion
(41.2%) and 17p abnormality (17.6%) were followed. MK deﬁned
by one single autosomal monosomy with at least one structural
chromosomal abnormality was detected in 44 patients (37%,
single monosomy group), and MK deﬁned by ⩾ 2 autosomal
monosomies was detected in 75 patients (63%, ⩾ 2 monosomy
group). Monosomies could be detected in every chromosome in
the ⩾ 2 monosomy group, but chromosomes 1, 3, 4, 6, 10, 15, 19,
21 and 22 were not affected in the single monosomy group.
Patients in the ⩾ 2 monosomy group were signiﬁcantly older and
exhibited lower white blood cell and platelet counts compared
with those in the single monosomy group (Table 1). Most patients
in the ⩾ 2 monosomy group exhibited CK with a higher incidence
of abn(17p) and − 5/del(5q) compared with those in the single
monosomy group. In contrast, the incidence of inv(3)/t(3;3) tended
to be higher in the single monosomy group. There were no other
signiﬁcant differences in the clinical characteristics between two
groups.
Therapeutic strategies and patient response
Patients received either one or two courses of myelosuppressive
induction chemotherapy; 108 (90.8%) received daunorubicin or
idarubicin in combination with cytarabine or the cytarabine
analog, N4-behenoyl-1-β-D-arabinofuranosylcytosine, 6 (5%)
received cytarabine combined with etoposide and 5 (4.2%)
received other chemotherapy regimens. Except 6 patients who
Table 1. Patient characteristics
Total patients, n= 119 Single monosomy, n=44 ⩾ 2 monosomies, n= 75 P-value
Median age (years) (range) 56 (17–82) 45.5 (17–78) 60 (23–82) 0.001
o 60, n (%) 69 (58.0) 34 (77.3) 35 (46.7)
⩾ 60, n (%) 50 (42.0) 10 (22.7) 40 (53.3)
Sex
Male/female 83/36 26/18 57/18 0.064
Type of AML
De novo, n (%) 100 (84.0) 38 (86.4) 62 (82.7) 0.595
Secondary, n (%) 19 (16.0) 6 (13.3) 13 (17.3)
WBC (×109/l) median (range) (n= 118) 5.83 (0.54–316.2) 10.41 (0.54–85.15) 3.68 (0.96–316.2) 0.045
Hemoglobin (g/dl), median (range) (n= 117) 8.2 (3.9–14.9) 8.5 (4.6–13.7) 8.1 (3.9–14.9) 0.133
Platelet count (×109/l), median (range) (n= 117) 55 (5–570) 70 (5–288) 52 (7–570) 0.033
PB blast, median % (range) (n= 103) 29 (0–100) 35.5 (0–94) 25 (0–100) 0.149
BM blast, median % (range) (n= 111) 52 (7.3–100) 61.3 (20–100) 44 (7.3–100) 0.189
Cytogenetic abnormalities
Complex (⩾3 clonal abnormalities), n (%) 106 (89.1) 32 (72.7) 74 (98.7) o0.001
Complex (⩾4 clonal abnormalities), n (%) 90 (75.6) 22 (50.0) 68 (90.7) o0.001
Inv(3)/t(3;3), n (%) 8 (6.7) 6 (13.6) 2 (2.7) 0.050
Abn11q23, n (%) 1 (0.8) 1 (2.3) 0 (0) 0.370
Abn(17p), n (%) 21 (17.6) 2 (4.5) 19 (25.3) 0.004
t(6;9), n (%) 4 (3.4) 2 (4.5) 4 (2.7) 0.626
− 5/del(5q), n (%) 49 (41.2) 7 (15.9) 42 (56.0) o0.001
− 7/del(7q), n (%) 56 (47.1) 19 (43.2) 37 (49.3) 0.516
Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; PB, peripheral blood; WBC, white blood cell count; y, years.
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were not available for assessment, 52 (46%) attained CR in
response to induction therapy (Figure 1). As a postremission
treatment, patients received 1–6 cycles of consolidation
chemotherapy according to each institution’s policy. Early/
hypoplastic death occurred in 12 patients (10.6%) and 49
(43.4%) exhibited a refractory response to induction therapy.
Finally, 43 patients underwent allo-HSCT: 33 of whom achieved CR
status (32 patients achieved CR1 or CR2 status after successful
induction therapy and 1 patient achieved CR1 with salvage
chemotherapy after failing two cycles of induction therapy),
whereas the remaining 10 patients had either relapsed or
demonstrated a refractory response at the time of allo-HSCT.
The median time interval between diagnosis and allo-HSCT was
4.7 months (range 2.4–13.3 months). The type of donor was an
HLA-matched sibling in 13 patients (30.2%), an HLA-matched
unrelated donor in 20 (46.5%) and a haploidentical donor in 10
(23.3%). As a conditioning regimen, myeloablative regimens were
used for 20 patients (46.5%), and reduced intensity conditioning
regimens based on ﬂudarabine was for the rest. Granulocyte-
colony-stimulating factor mobilized peripheral blood stem cells in
the majority of stem cell source (86.0%).
Prognostic factors for the response to induction therapy
Supplementary Table 1 illustrates the response of patients to
induction therapy and the affecting factors. CR rate decreased
with age as a numerical variable (1-year old, P= 0.008), and the
presence of ⩾ 10% of cells with normal metaphase was another
good prognostic factor for CR after induction therapy (P = 0.002) in
univariate analysis. Older age (⩾60 years) and secondary AML
were associated with lower CR rate of 37% and 26.3%,
respectively, although this was not signiﬁcant. The number of
monosomies did not impact patients’ response to induction
therapy (P= 0.758). In multivariate analysis, a younger age
(P = 0.023) and the presence of ⩾ 10% of cells with normal
metaphase still signiﬁcantly correlated with a higher rate of CR
achievement (P= 0.005). The factors associated with a higher
incidence of early/hypoplastic death included the percent of cells
with normal metaphase (P = 0.033) and the presence of abn(17p)
(P = 0.037) (Supplementary Table 2).
Prognostic factors for survival outcome
The median follow-up time was 39.4 months from diagnosis. The
median OS and EFS were 8.1 months (95% conﬁdence interval (CI),
range 6.5–9.8 months) and 4.6 months (95% CI, range
3.1–6.1 months), respectively (Supplementary Table 3). The 3-year
OS and EFS rates were 19.6% and 7.3%, respectively. Interestingly,
previously well-known prognostic factors for AML, including a
high white blood cell count at diagnosis, subtype of AML, CK and
adverse cytogenetic abnormalities, with the exception of abn
(17p), did not show any inﬂuence on OS (Supplementary Table 3).
Age o60 years, the achievement of CR after induction therapy,
single monosomy subtype, the presence of ⩾ 10% of cells with
normal metaphase and the absence of abn(17p) were associated
with better OS in univariate analysis. CK (⩾4 clonal abnormalities)
tended to affect survival outcome, although this was not
statistically signiﬁcant. In multivariate analysis, the achievement
of CR after induction therapy, single monosomy subtype, the
presence of ⩾ 10% of cells with normal metaphase and the
absence of abn(17p) remained independent prognostic factors for
better OS (Table 2). The achievement of CR after induction therapy
(Po0.001), single monosomy (P= 0.019) and the diagnosis of de
novo AML (P= 0.027) signiﬁcantly correlated with higher EFS rates
in multivariate analysis. Next, the positive impact of single
monosomy subtype in patients without CK (⩾4 clonal abnormal-
ities) was analyzed, and single monosomy subtype has kept its
positive prognostic impact on OS in patients without CK (P= 0.044;
Figure 2a). Conversely, in the single monosomy group, CK did not
impact OS (P= 0.401; Figure 2b).
The beneﬁcial effect of allo-HSCT in MK-AML
Of 52 patients achieving CR after induction therapy, 32 underwent
allo-HSCT in CR; 13 (59%) of 22 patients with single monosomy
and 19 (63%) of 30 patients with ⩾ 2 monosomies underwent allo-
HSCT in CR. Table 3 shows the result of multivariate analyses for
OS and RFS in patients who achieved CR after induction therapy.
In multivariate analysis, single monosomy subtype (hazard ratio
(HR): 0.314, 95% CI: 0.135–0.732; P= 0.007) and allo-HSCT in CR
(HR: 0.268; 95% CI: 0.090–0.798; P= 0.018) were independent
predictive factors for better OS (Table 3). Although allo-HSCT in CR
improved survival in patients achieving CR after induction therapy
(P = 0.020; Figure 3a), allo-HSCT as a salvage treatment (n= 8) did
Figure 1. Flow diagram of patients. CTx, chemotherapy; NR, non-remission.
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not show survival beneﬁt compared with salvage chemotherapy
(n= 12) for relapsed or refractory patients (P = 0.675; Figure 3b).
In this comparison, patients with early/hypoplastic death during
induction therapy were excluded.
Subgroup analysis for biologic prognostic factors of MK-AML
Because allo-HSCT as postremission therapy has an important
prognostic power for AML patients, we further performed
subgroup analysis according to the type of postremission therapy.
One patient who underwent transplantation in CR1 status after
failing two cycles of induction therapy followed by salvage
chemotherapy was excluded for analysis. Especially for 32 patients
who received allo-HSCT in CR, univariate and multivariate analyses
were performed for OS using Cox regression tests (Supplementary
Table 4). The independent prognostic factor for a better OS
for those was single monosomy subtype (HR: 0.273; 95% CI:
0.087–0.863; P= 0.027). The beneﬁcial impact of allo-HSCT in CR
was not equally distributed in patients with single monosomy or
⩾ 2 monosomies. The 3-year OS after allo-HSCT in CR for patients
with single monosomy was 64.6%, and allo-HSCT in CR improved
OS signiﬁcantly in patients with single monosomy (P= 0.005;
Figure 4a). However, in patients with ⩾ 2 monosomies, no
beneﬁcial impact of allo-HSCT could be demonstrated (P= 0.249;
Figure 4b). Next, another 86 patients who did not receive allo-
HSCT in CR were analyzed to evaluate biological prognostic factors
of MK-AML, excluding the therapeutic variable. Similar with the
result of the analyses for the total 119 patients, multivariate
analysis for these subgroup showed that the achievement of CR
after induction therapy (P= 0.002), single monosomy subtype
(P= 0.025), the presence of ⩾ 10% of cells with normal metaphase
(P= 0.019) and the absence of abn(17p) (P= 0.027) correlated
signiﬁcantly with better OS rates (Supplementary Table 5).
Patients with single monosomy showed superior OS compared
with patients with ⩾ 2 monosomies, irrespective of the inclusion of
patients who received allo-HSCT in CR (P= 0.016 when these
patients were excluded (Figure 5a) and P= 0.002 (Figure 5b) when
these patients were included).
DISCUSSION
In this study, we retrospectively analyzed MK-AML patients using a
nationwide database from South Korean AML Registry to evaluate
the predictive factors for better prognoses and to feature out
clinical heterogeneity of patients according to the type of MK.
MK-AML accounted for ~ 5.7% of Korean AML population, and
was associated with lower CR rate after induction therapy and
extremely poor outcomes, which is consistent with previous
studies.5,7,16
Notwithstanding a dismal prognosis, multivariate analysis
revealed that single monosomy, ⩾ 10% cells with normal
metaphase, the absence of abn(17p) and achievement of CR after
induction therapy were prognostic factors for better OS in
Korean MK-AML patients. Single monosomy was also a prognostic
factor for better OS in patients who received allo-HSCT in CR.
Figure 2. OS of (a) patients not having complex karyotype (⩾4)
according to monosomal karyotype subtype, and (b) patients with
single monosomy according the degree of clonal abnormalities (⩾4
versus o4).
Table 2. Multivariate analysis of prognostic factors for OS and EFS in 119 patients with MK-AML
Overall survival Event-free survival
HR (95% CI) P-value HR (95% CI) P-value
Age (o60 years) 0.868 (0.540–1.397) 0.561 0.940 (0.609–1.449) 0.778
Single monosomy 0.460 (0.274–0.772) 0.003 0.514 (0.294–0.897) 0.019
Complex (⩾4 clonal abnormalities) — 0.879 (0.481–1.607) 0.676
⩾ 10% Cells with normal metaphase 0.511 (0.311–0.841) 0.008 0.692 (0.447–1.071) 0.098
De novo AML — 0.525 (0.297–0.930) 0.027
Absence of abn(17p) 0.532 (0.311–0.911) 0.022 0.708 (0.411–1.219) 0.213
Achievement of CR after induction Tx 0.238 (0.143–0.396) o0.001 0.264 (0.168–0.416) o0.001
Abbreviations: AML, acute myeloid leukemia; CI, conﬁdence interval; CR, complete remission; EFS, event-free survival; HR, hazard ratio; MK, monosomal
karyotype; OS, overall survival; Tx, therapy.
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The number of monosomies directly correlates with a poor
prognosis in AML.5–7 To our knowledge, the signiﬁcance of the
prognostic value of a single monosomy in MK-AML has not been
reported. In our study, patients in the ⩾ 2 monosomy group were
older and had a higher incidence of abn(17p) and − 5/del(5q), and
in multivariate analysis of PFS, single monosomy remained as a
signiﬁcant factor for better PFS, whereas age, abn(17p) or − 5/del
(5q) had not a signiﬁcant impact on PFS. The tumor suppressor
gene TP53, located in the commonly deleted region, 17p13, is
associated with a higher degree of genomic complexity and very
Table 3. Multivariate analysis of clinical outcome in 52 patients who achieved CR after induction therapy
Overall survival Relapse-free survival
HR (95% CI) P-value HR (95% CI) P-value
Single monosomy 0.314 (0.135–0.732) 0.007 0.237 (0.092–0.615) 0.003
WBC o50 ×109/l — — 0.177 (0.050–0.628) 0.007
De novo AML — — 0.098 (0.024–0.404) 0.001
Absence of abn(17p) — — 0.435 (0.164–1.152) 0.179
Allo-HSCT in CR 0.268 (0.090–0.798) 0.018 0.249 (0.099–0.626) 0.003
Abbreviations: Allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; CI, conﬁdence interval; CR, complete remission;
HR, hazard ratio; WBC, white blood cell count.
Figure 3. Kaplan–Meier curves for OS (a) according to the receipt of
allo-HSCT for consolidation in patients who achieved CR after
induction therapy and (b) according to the receipt of allo-HSCT as
salvage treatment in patients who did not achieve CR after
induction therapy.
Figure 4. Kaplan–Meier estimate for OS according to the receipt of
allo-HSCT in CR for consolidation in patients who achieved CR after
induction therapy and (a) have a single monosomy or (b) have ⩾ 2
monosomies.
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poor prognosis.17–19 Several studies have reported that TP53
mutations were associated with del(5q) or del(17p).20,21 TP53
alterations have been described in nearly 54–80% of MK-AML
cases.22 A dysfunction in the TP53 pathway contributes to an
increase in chromosomal instability. The presence of abn(17p) is
also an adverse risk factor in AML;23,24 however, the signiﬁcance of
abn(17p) in MK-AML is not clear. Middeke et al.10 reported that
MKs lose their poor prognostic value in patients who have
undergone allo-HSCT when those with abn(17p) or − 5/del(5q) are
excluded. However, Breems et al.25 reported that MK retains its
notoriously adverse prognostic value and does not depend on the
inclusion of AML patients with abn(17p) and − 5/del(5q). In our
analysis, abn(17p), not − 5/del(5q), had a signiﬁcant adverse effect
among MK-AML patients. The cohort of Middeke’s study included
elderly patients with a median age of 55 years with a range
of 22–77 years, and the cohort of Breems’s study included patients
aged 15–60 years. The current study also included elderly patients
with a wide age range. We found that patients with abn(17p) were
signiﬁcantly older than patients without abn(17p) in our cohort.
Older MK-AML patients may be more affected by abn(17p) as the
incidence is higher. Nevertheless, in multivariate analysis, abn(17p)
still remained a signiﬁcant impact factor for better OS, whereas
age did not. The differences in prognosis between MK with single
monosomy and ⩾ 2 monosomies could be biologically explained
by the different incidence of the TP53 mutation-associated
chromosomal abnormalities in both groups. Further research has
to be needed to determine which genomic alterations are mainly
associated with the prognostic cytogenetic features demonstrated
in this study.
In addition to a single monosomy and the absence of abn(17p),
⩾ 10% of cells with normal metaphase was also important
prognostic factors. The presence of ⩾ 10% of cells with normal
metaphase was a prognostic factor for OS and a signiﬁcant
contributor to achieving CR. A higher percent of normal cells in
MK-AML has been reported to be associated with longer
survival.11 How residual normal metaphases translate to longer
survival is unclear. We demonstrated that having ⩾ 10% of cells
with normal metaphase was associated with a higher rate of CR
after induction therapy and longer OS. The fact that the
achievement of CR is a critical factor for long-term survival in
MK-AML may explain why having ⩾ 10% of cells with normal
metaphase was associated with longer survival.
Allo-HSCT is currently the recommended consolidation treat-
ment for poor-risk AML.26,27 However, several studies have
reported contrasting results regarding the beneﬁt of allo-HSCT
in patients achieving a CR after induction therapy,7,12,13,28 and
thus more research is necessary to deﬁne clearly the subgroups of
MK-AML that would beneﬁt from allo-HSCT. Our analysis demon-
strated distinct differences in survival after allo-HSCT in CR
depending on the karyotypic subtype of MK, single monosomy
or ⩾ 2 monosomies. The beneﬁcial role of allo-HSCT in CR was
identiﬁed only in patients with single monosomy, and the 3-year
OS of patients with single monosomy who received allo-HSCT in
CR was 64.6% in this study. This survival outcome is comparable
with the 3-year OS rate of patients without MK reported by Fang
et al.13 Although it is hard to compare the results directly, MK-AML
with single monosomy might need to be distinguished from the
very poor-risk group.
In our study, because allo-HSCT in CR improved outcomes, we
separately analyzed patients grouped by the receipt of allo-HSCT
in CR to exclude the effect of the therapeutic factor in overcoming
a poor prognosis. The independent prognostic factor in both
groups was having a single monosomy. This result suggests that
MK-AML with single monosomy may be biologically different from
MK-AML with ⩾ 2 monosomies and the investigation of genetic
differences is necessary.
This study has several limitations, including its retrospective
design and the fact that the therapeutic strategies after induction
therapy were chosen at the discretion of physicians and according
to each institution’s policy. However, therapeutic strategies in a
single nation’s medical system are relatively similar, and clinical
variables that may affect clinical outcomes would be comparable
among patient subgroups. Moreover, nationwide database, which
was used for analysis in this study, was centrally collected by the
Korean Society of Hematology to secure the objectivity.
In summary, although MK-AML was generally regarded as very
poor-risk factor, patients with single monosomy, the absence of
abn(17p) or ⩾ 10% of cells with normal metaphase experienced
better prognosis than expected. Allo-HSCT had beneﬁcial effect on
prognosis when performed in CR status but not in relapsed/
refractory status. However, Allo-HSCT in CR was associated with
superior survival rates only in patients with a single monosomy.
Interestingly, for those who did not receive allo-HSCT as
postremission therapy, single monosomy was also an important
favorable prognostic factor. Allo-HSCT in CR should be strongly
recommended to MK-AML patients with a single monosomy, and
for those with ⩾ 2 monosomies, more prudent treatment regi-
mens are required. MK-AML with single monosomy might be
biologically different from MK-AML with ⩾ 2 monosomies, and the
biological mechanism by which these cytogenetic features
inﬂuence patient prognosis should be further investigated.
Figure 5. Kaplan–Meier estimate for OS according to the number of
monosomies (a) in 86 patients, except those who received allo-HSCT
in CR and (b) of 119 MK-AML patients.
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